{"title": "Hepatitis C", "author": "Juan Carlos Restrepo Guti\u00e9rrez; Ana Isabel Toro Montoya", "url": null, "hostname": null, "description": "Hepatitis C is a disease caused by hepatitis C virus and is the leading cause of cirrhosis and liver transplantation in the Western world. It is estimated that 3% of the world population is infected with this virus. Most infections are asymptomatic or can manifest nonspecific symptoms like fatigue, nausea, myalgia and fever, which can make the initial diagnosis more difficult. In the progression of the disease to the chronic stage, several factors can participate, including viral, host and external factors. The finding of abnormal laboratory tests or signs of cirrhosis should make the clinician consider hepatitis C. For the diagnosis, there are serological and virological assays available; serological assays detect antibodies against the virus, while virological assays can detect the viral RNA. The wide variety of quasispecies and the virus variability have not allowed the synthesis of a vaccine that provides protection.", "sitename": "Medicina y Laboratorio", "date": "2011-09-01", "cleaned_text": "Hepatitis C Resumen La hepatitis C es una enfermedad causada por el virus de la hepatitis C y es la principal causa de cirrosis y trasplante hep\u00e1tico en el mundo occidental. Se estima que el 3% de la poblaci\u00f3n mundial est\u00e1 infectada por este virus. La mayor\u00eda de las infecciones son asintom\u00e1ticas y cuando se manifiestan aparecen s\u00edntomas inespec\u00edficos como fatiga, n\u00e1usea, mialgias y fiebre, que pueden hacer dif\u00edcil el diagn\u00f3stico inicial. En la progresi\u00f3n de la enfermedad a la etapa cr\u00f3nica participan factores relacionados con el virus, el hospedero y tambi\u00e9n algunos factores externos. El hallazgo de unas pruebas de laboratorio anormales o signos de cirrosis debe hacer pensar en una hepatitis C. Para el diagn\u00f3stico se dispone de pruebas serol\u00f3gicas y virol\u00f3gicas; las serol\u00f3gicas detectan anticuerpos contra el virus, en tanto que las virol\u00f3gicas detectan el RNA viral. La gran variedad de cuasiespecies y la variabilidad del virus de la hepatitis C no han permitido hasta ahora la s\u00edntesis de una vacuna que brinde protecci\u00f3n. Descargas Referencias bibliogr\u00e1ficas Senecal DL, Morelli J. Hepatitis C virus 2007; [http://www.hcvadvocate.org](http://www.hcvadvocate.org). Accesado bre 3 AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975; 292: 767-770. determinants of TRIF proteolysis mediated natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; Feinstone S, al. Consensus proposals for a unified system M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. E2, and hypervariable region 1 T, Dubuisson J, Wychowski C, al. C Lemon SM, Walker CM, Alter MJ, Yi M. Hepatitis C virus. In: Knipe DM, Howley PM (eds). Fields Virology, 5th edition. Lipincott Williams & Wilkins Pubishers; pp. 1253-1304, 2007. Lancet Infect Dis 2005; 5: 558-567. [https://doi.org/10.1016/S1473-3099(05)70216-4](https://doi.org/10.1016/S1473-3099(05)70216-4) World Global alert and response. [http://www.who.int/csr/disease/hepatitis/](http://www.who.int/csr/disease/hepatitis/) whocdscsrlyo2003/en/index.html. Accesado en agosto 30 de epidemiology [https://doi.org/10.1016/S1590-8658(01)80695-2](https://doi.org/10.1016/S1590-8658(01)80695-2) Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, et al. Higher clearance of hepa- titis Riquelme A, Arrese M. of transmission of hepatitis C virus. Ann Hepatol 2010; 9 Suppl: 33. [https://doi.org/10.1016/S1665-2681(19)31720-X](https://doi.org/10.1016/S1665-2681(19)31720-X) Paintsil C, Lindenbach BD, Heimer R. Survival of hepatitis D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010; 81: 1351-1357. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S. [https://doi.org/10.1016/S0002-9343(99)00373-3](https://doi.org/10.1016/S0002-9343(99)00373-3) Dwyre DM, Fernando LP, patitis C and HIV Lackritz E, et al. Prevalence and screening costs of hepatitis C virus among Ugandan donors. Trop Int Health 2006; 11: 951-954. [https://doi.org/10.1111/j.1365-3156.2006.01643.x](https://doi.org/10.1111/j.1365-3156.2006.01643.x) Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use associated Hickman M. Estimates of injecting drug users at local level in developing and transitional countries, and gender iii10-17. O, Ochoa-Jimenez RJ, et Y, De Carli G, Migueres B, Lot F, Cam- pins M, Colombo C, et al. Risk factors for hepatitis C virus transmission to health care workers occu- Oral Dis 2008; 14: 10-14. [https://doi.org/10.1111/j.1601-0825.2007.01419.x](https://doi.org/10.1111/j.1601-0825.2007.01419.x) Thomas DL, Seeff LB. Natural 9: 383-398, vi. 2006; 55: 1075-1077. [https://doi.org/10.1136/gut.2005.085407](https://doi.org/10.1136/gut.2005.085407) Latin American Association for the Study of the Li- ver Practice Guidelines. Diagnosis, management, and treatment of Ann Hepatol 2010; 9 Suppl: 8-26. [https://doi.org/10.1016/S1665-2681(19)31717-X](https://doi.org/10.1016/S1665-2681(19)31717-X) H, Rojas W, Borrero J, Restrepo J, editors. Fundamentos de Medi- cina. Enfermedades infecciosas. Editorial Corporaci\u00f3n para Investigaciones Biol\u00f3gicas CIB. Sexta edici\u00f3n; 2003. p. 169-174. Alberti A, Vario A, Ferrari A, Pistis R. Review Estrella MM, Lucas GM, Sperati CJ, Atta MG, et al. The Impact of Hepatitis Kidney [https://doi.org/10.1097/MD.0b013e31822f5915](https://doi.org/10.1097/MD.0b013e31822f5915) MS. Hepatitis C virus in the set- ting of HIV or hepatitis B of hepatitis B virus. 45: 613-617. [https://doi.org/10.1136/gut.45.4.613](https://doi.org/10.1136/gut.45.4.613) Hepatitis Foundation International. [http://www.hepfi.org](http://www.hepfi.org). Accesado el 10 de octubre de 2011. Orland JR, Wright TL, Cooper S. Acute FA, Schaeffer M, Galai N, et al. The natural history of he- patitis C virus infection: Carvajal JJ, Correa G, Restrepo JC. Hepatitis C aguda. Revisi\u00f3n de un caso. Acta Med Colomb 2008; 33: 28- 32. Merican I, histological patients J Foster N. The impact of diagnosis of hepatitis C virus qua- lity on health rela- ted 1463-1466. Bruno Maisonneuve P, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a ma- jor risk factor associated with hepatocellular carcinoma in patients et al. Morbidity mortality in compensated cirrhosis type C: C virus-related cirrhosis and history of the United States. Hepatology 1999; 29: 1311-1316. Cazzato M, Lon- gombardo G, Antonelli thogenesis, natural history, treatment, and Friedman LS, Brandt Feldman: an imprint of Elsevier; pp. 1313-1331, 2010. Asociaci\u00f3n Espa\u00f1ola para el Estudio del H\u00edgado, Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda, Asocia- ci\u00f3n Latinoamericana para el Estudio del H\u00edgado, Asociaci\u00f3n Interamericana de Gastroenterolog\u00eda. Consenso para el tratamiento de las hepatitis B y C. Gastroenterol Hepatol Diag- nosis, management, and 49: 1335-1374. 2001; 298. Maheshwari Dis 2010; 14: 169-176; x. [https://doi.org/10.1016/j.cld.2009.11.007](https://doi.org/10.1016/j.cld.2009.11.007) Lauer GM, Walker BD. Hepatitis J Med 2001; Tanaka Y, Mizokami M, Iwasaki M, Tsugane S. Impact of viral load of hepatitis C on the incidence of hepatocellular N, S, Gonzalez- Peralta RP, Kelly D, et Gastroenterol Nutr v\u00edricas agudas. In: ed. Hepatolog\u00eda, 1a ed. M\u00e9xico, DF: Mc- Graw Hill; pp. 75-89, 2007. De la Vega A, Frauca E. Conducta ante la hepatitis por el VHC. In: Jara P, Coordinadora. Protocolos diagn\u00f3sti- MM, McBurney R, Park Y, Haynes- Williams V, Rehermann B, et al. The natural history of acute hepatitis C: clinical Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic M, Sweeting M, DeAn- gelis D, Rosenberg W, et al. Cost effectiveness of in- terferon alpha or peginterferon alpha E, Conrads-Frank Wright D, et al. Long-term effecti- veness and cost-effectiveness of antiviral treatment "}